knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 18:33:35 - browse：1847

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Virtual care provider acquires bankrupt Pear's prescription apps

hotspot

WSS

Hospitals owned by private equity see complications spike 25%

Grail spinoff by Illumina should end disastrous merger attempt

How Long Island became the ‘eugenics capital of the world’

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

What AAP's gender

leisure time

knowledge

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Virtual care provider acquires bankrupt Pear's prescription apps

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: The latest on Moderna, Apellis, and Merck

At least 13 dead in Texas as scorching temps continue

In science, is the line between industry and academia shifting?

Medicare proposal to cover medical devices draws a mixed reaction

In science, is the line between industry and academia shifting?

As demand for Covid shots wanes, Moderna seeks its next success

In Spain, a hospital brews its own CAR

explore

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Why more medical students aren't specializing in primary care

AstraZeneca challenges Medicare drug negotiation program

AstraZeneca bets AAV gene therapy will still deliver the goods

Hospitals owned by private equity see complications spike 25%

How to make AI work for medicine

hotspot

hotspot

hotspot

knowledge